---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-022466"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:15:58.283638+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy

## Summary
- Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.
- FDA cleared IND for PM359 for chronic granulomatous disease—first Prime Editing product to enter clinic.
- Phase 1/2 trial planned; initial clinical data expected in 2025.
- Appointed Tony Coles, M.D. as senior advisor; brings biopharma leadership.
- Presented preclinical data at ASGCT supporting specificity and delivery of Prime Editing platform.

## SEC filing metadata
- accession: 0001628280-24-022466
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/prme-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-022466
- JSON: https://secwatch.observer/filing/0001628280-24-022466.json
- Plain text: https://secwatch.observer/filing/0001628280-24-022466.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: today reported financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.